NCT04447755 : An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Malignancies

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

2-21Age 2-21

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy,Treatment | Brain and spinal cord,Female reproductive organs,Head and neck,Sarcoma,Stomach and upper gastrointestinal tract,Urinary systemBone,Chondrosarcoma,Ewing's Sarcoma,Germ cell and sex cord stromal cell,Germ cell tumour,Kidney,Leiomyosarcoma,Liposarcoma,Liver,Neuroblastoma,Ovary,Rhabdomyosarcoma,Sarcoma,Soft Tissue Sarcoma,Synovial Sarcoma,Testis,Thyroid,Wilm's tumour

Trial Overview Read MoreRead more

This study is evaluating how safe a type of targeted therapy (Lenvatinib) is for the treatment of children, adolescents, and young adults with relapsed or refractory cancer.
 

This trial is treating patients with relapsed or refractory solid cancer, excluding osteosarcoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Malignancies

Commercial Sponsor

Merck

Summary

Participants will be enrolled into initial tumor-specific cohorts which will be expanded based on observed response. Participants will receive 14 mg/m^2 oral lenvatinib, once daily (QD) until progressive disease or unacceptable toxicity (up to approximately 1 year).

Recruiting Hospitals Read MoreRead more

Royal Childrens Hospital
Parkville
Trial Coordinator
CCC.ClinicalTrials@rch.org.au

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next